📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Both cladribine and alemtuzumab may effect MS via B-cell depletion. (2017)

First Author: Baker D

Attributed to: MidPlus: A Centre of Excellence for Computational Science, Engineering and Mathematics funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1212/nxi.0000000000000360

PubMed Identifier: 28626781

Publication URI: http://europepmc.org/abstract/MED/28626781

Type: Journal Article/Review

Volume: 4

Parent Publication: Neurology(R) neuroimmunology & neuroinflammation

Issue: 4

ISSN: 2332-7812